Galectin Therapeutics Inc.
GALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $80,379 | $99,864 | $67,112 | $121,151 |
| - Cash | $15,120 | $25,660 | $18,592 | $39,648 |
| + Debt | $106,245 | $71,807 | $39,868 | $29,056 |
| Enterprise Value | $171,504 | $146,011 | $88,388 | $110,559 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$37 | -$33 | -$32 | -$41 |
| % Margin | – | – | – | – |
| EBITDA | -$41,470 | -$38,241 | -$37,711 | -$29,997 |
| % Margin | – | – | – | – |
| Net Income | -$47,047 | -$41,066 | -$38,776 | -$30,527 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.76 | -0.74 | -0.65 | -0.52 |
| % Growth | -2.7% | -13.8% | -25% | – |
| Operating Cash Flow | -$41,767 | -$32,965 | -$31,056 | -$24,308 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$41,767 | -$32,965 | -$31,056 | -$24,308 |